Cue Biopharma (CUE) Total Debt (2022 - 2025)

Cue Biopharma (CUE) posted Total Debt of $689000.0 for Q4 2025, down 58.19% sequentially from $1.6 million in Q3 2025.

Cue Biopharma (CUE) Total Debt (2022 - 2025) Analysis & Trends

Cue Biopharma has reported Total Debt for 4 years, with the latest figure at $689000.0 in Q4 2025.

Quarterly Total Debt changed N/A year-over-year to $689000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $689000.0 (changed N/A YoY) and the FY2025 annual result came in at $689000.0, changed N/A from the prior year.
Total Debt slipped to $689000.0 in Q4 2025 per CUE's latest filing, from $1.6 million in the prior quarter.
Over five years, Total Debt peaked at $10.0 million in Q1 2023 and troughed at $689000.0 in Q4 2025.
A 4-year average of $6.3 million and a median of $7.2 million in 2024 frame the typical range for Total Debt.
The sharpest annual moves came in 2023 and 2025: Total Debt soared 731.02% in 2023, then tumbled 67.04% in 2025.
Over 4 years, Total Debt stood at $10.0 million in 2022, then fell by 18.33% to $8.2 million in 2023, then tumbled by 38.76% to $5.0 million in 2024, then slumped by 86.22% to $689000.0 in 2025.
According to Business Quant data, Total Debt over the past three periods registered $689000.0, $1.6 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	Cue Biopharma	152.56 Mn	135.14 Mn	-	960,000.00

Download Data